poisar

Stocks · News reference

Reported Earlier, Telix Reaffirms FY 2026 Revenue And Other Income Above $1B, Tracking Toward Upper End Of $950M-$970M Revenue Guidance, Revises R&D Spend Guidance To $240M-$260M

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncTelix Pharmaceuticals Limited

    Telix Reports Third Quarter 2026 Financial Performance

    Telix Pharmaceuticals reported Q3 2026 group revenue of US$245 million, up 19% year-over-year, driven by strong demand for PSMA imaging products Gozellix and Illuccix. The company received FDA approval for Pixclara for glioma imaging and announced a transformational merger with Isotope Technologies Munich (ITM) for US$1.65 billion upfront, creating a vertically integrated radiopharmaceutical company with expanded isotope production capabilities. Telix reaffirmed FY 2026 revenue guidance exceeding US$1 billion.

  2. Globenewswire IncNa

    Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

    Telix Pharmaceuticals has partnered with Ekalia (a joint venture between IBA and Framatome) to establish dedicated U.S. production of astatine-211, a scarce alpha-emitting isotope for targeted alpha therapy. The collaboration will install IBA's alpha-beam cyclotron at Telix's RLS Radiopharmacies site near Philadelphia, securing long-term isotope access for Telix's pipeline including TLX102-Tx for glioblastoma, while also supporting third-party programs.